[go: up one dir, main page]

MA32271B1 - Composes inhibiteurs de kinases raf et procedes d'utilisation - Google Patents

Composes inhibiteurs de kinases raf et procedes d'utilisation

Info

Publication number
MA32271B1
MA32271B1 MA33202A MA33202A MA32271B1 MA 32271 B1 MA32271 B1 MA 32271B1 MA 33202 A MA33202 A MA 33202A MA 33202 A MA33202 A MA 33202A MA 32271 B1 MA32271 B1 MA 32271B1
Authority
MA
Morocco
Prior art keywords
methods
reg
inhibitory compounds
kinase inhibitory
compounds
Prior art date
Application number
MA33202A
Other languages
Arabic (ar)
English (en)
Inventor
Kateri A Ahrendt
Alexandre J Buckmelter
Jonas Grina
Joshua D Hansen
Ellen R Laird
David Moreno
Brad Newhouse
Li Ren
Steven Mark Wenglowsky
Bainian Feng
Janet Gunzner
Kim Malesky
Simon Mathieu
Joachim Rudolph
Zhaoyang Wen
Wendy B Young
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of MA32271B1 publication Critical patent/MA32271B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Des composés de formule i sont utiles pour inhiber des kinases raf. La présente invention concerne des procédés d'utilisation de composés de formule i, ainsi que des stéréo-isomères, des tautomères, des promédicaments, et des sels pharmaceutiquement acceptables de ceux-ci, en vue du diagnostic, de la prévention, ou du traitement, in vitro, in situ, et in vivo, de ces troubles dans les cellules de mammifères. La présente invention concerne également des conditions pathologiques associées.
MA33202A 2008-02-29 2010-09-24 Composes inhibiteurs de kinases raf et procedes d'utilisation MA32271B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3283908P 2008-02-29 2008-02-29
PCT/US2009/035380 WO2009111278A2 (fr) 2008-02-29 2009-02-27 Composés inhibiteurs de kinases raf et procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA32271B1 true MA32271B1 (fr) 2011-05-02

Family

ID=40935896

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33202A MA32271B1 (fr) 2008-02-29 2010-09-24 Composes inhibiteurs de kinases raf et procedes d'utilisation

Country Status (16)

Country Link
US (1) US8338452B2 (fr)
EP (1) EP2265608A2 (fr)
JP (1) JP2011513330A (fr)
KR (1) KR20100122505A (fr)
CN (1) CN102015707A (fr)
AR (1) AR070535A1 (fr)
AU (1) AU2009222143A1 (fr)
CA (1) CA2716951A1 (fr)
CL (1) CL2009000447A1 (fr)
EC (1) ECSP10010510A (fr)
IL (1) IL207843A0 (fr)
MA (1) MA32271B1 (fr)
MX (1) MX2010009410A (fr)
PE (1) PE20091561A1 (fr)
TW (1) TW200940540A (fr)
WO (1) WO2009111278A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TW200940539A (en) * 2008-02-29 2009-10-01 Array Biopharma Inc RAF inhibitor compounds and methods of use thereof
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
WO2009111277A1 (fr) * 2008-02-29 2009-09-11 Array Biopharma Inc. Dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de raf
FR2941948B1 (fr) * 2009-02-12 2013-04-05 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
BRPI1008709B8 (pt) 2009-04-03 2021-05-25 Hoffmann La Roche dispersão sólida, formulação, composição e comprimido compreendendo {3-[5-(4-cloro-fenil)-1h-pirrol[2,3-b]piridina-3-carbonil]-2,4-diflúor-fenil}-amida do ácido propano-1-sulfônico
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US20110112127A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
MY162950A (en) 2011-02-07 2017-07-31 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
KR20190133790A (ko) 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
JP2014534949A (ja) 2011-09-19 2014-12-25 ジェネンテック， インコーポレイテッド Ｃ−ｍｅｔアンタゴニストおよびｂ−ｒａｆアンタゴニストを含む組合せ処置
AU2012376221A1 (en) * 2011-10-31 2014-06-19 David S. Baskin Compound comprising a MAO targeting/ seeker moiety for treating human gliomas
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR20240146112A (ko) 2012-08-17 2024-10-07 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
FR3000494B1 (fr) * 2012-12-28 2015-08-21 Oribase Pharma Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases
FR3000492B1 (fr) 2012-12-28 2015-09-11 Oribase Pharma Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
FR3000493A1 (fr) * 2012-12-28 2014-07-04 Oribase Pharma Nouveaux inhibiteurs de proteines kinases
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
KR20160013028A (ko) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 그에 대한 적응증
JP6224832B2 (ja) * 2013-08-02 2017-11-01 ファイザー・インク Ｒｏｒｃ２阻害薬およびその使用方法
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2015196072A2 (fr) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Utilisations d'inhibiteurs de kinase pour l'induction et le maintien de la pluripotence
JP6673896B2 (ja) 2014-07-15 2020-03-25 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びｍｅｋ阻害剤を使用した癌を処置するための組成物
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
JP6952691B2 (ja) 2015-11-19 2021-10-20 ジェネンテック， インコーポレイテッド Ｂ−ｒａｆ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法
WO2018146253A1 (fr) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk
EP3732285A1 (fr) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Systèmes de culture de cellules souches pour cellules souches épithéliales colonnaires, et leurs utilisations
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
PE20221027A1 (es) * 2019-12-10 2022-06-16 Hoffmann La Roche Nuevos inhibidores de braf como rompedores de la paradoja
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025073765A1 (fr) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de mélanome
WO2025080946A2 (fr) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ186175A (en) * 1977-01-27 1980-03-05 Shionogi & Co Meta-sulphonamidobenzamide derivatives
SK285371B6 (sk) 1997-12-22 2006-12-07 Bayer Corporation Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom
DE69829412T2 (de) 1997-12-22 2005-07-28 Bayer Pharmaceuticals Corp., West Haven Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
NZ505844A (en) 1997-12-22 2003-10-31 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
ME00275B (fr) * 1999-01-13 2011-02-10 Bayer Corp DIPHENYLUREES A SUBSTITUANTS ω-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
JP2002534468A (ja) * 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
EP1140840B1 (fr) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030207914A1 (en) * 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2003068773A1 (fr) 2002-02-12 2003-08-21 Glaxo Group Limited Derives de pyrazolopyridine
ATE447404T1 (de) * 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US7645771B2 (en) * 2002-12-13 2010-01-12 Smithkline Beecham Corp. CCR5 antagonists as therapeutic agents
WO2004108133A2 (fr) 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulateurs du recepteur vr1
WO2004110452A1 (fr) * 2003-06-13 2004-12-23 Novartis Ag Derives de 2-aminopyrimidine utilises comme inhibiteurs de raf kinase
CA2531859C (fr) * 2003-07-11 2013-08-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Derives de benzimidazoles utilises comme inhibiteurs de kinase raf
JP5001650B2 (ja) * 2003-07-11 2012-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンズイミダゾールカルボキサミド
DE10337942A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
KR100793095B1 (ko) 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
JP4758349B2 (ja) * 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
AU2004281151A1 (en) * 2003-10-16 2005-04-28 Novartis Vaccines And Diagnostics, Inc. Substituted benzazoles and use thereof as inhibitors of Raf kinase
AU2004281154A1 (en) * 2003-10-16 2005-04-28 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
US20090118261A1 (en) * 2004-08-31 2009-05-07 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
CA2577278A1 (fr) * 2004-09-01 2006-03-09 Astrazeneca Ab Derives de quinazolinone et utilisation de ces derives en tant qu'inhibiteurs du b-raf
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2583096A1 (fr) * 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines en tant qu'inhibiteurs b-raf
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
UY29300A1 (es) 2004-12-22 2006-07-31 Astrazeneca Ab Compuestos quimicos
CN101087787A (zh) 2004-12-23 2007-12-12 霍夫曼-拉罗奇有限公司 苯甲酰胺衍生物，它们的制备及作为药剂的应用
JP5197016B2 (ja) * 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ， エルエルシー 酵素モジュレータ及び治療
KR20070107061A (ko) * 2005-01-25 2007-11-06 아스트라제네카 아베 화학적 화합물
CA2593803A1 (fr) * 2005-01-26 2006-08-03 Irm Llc Composes et compositions utilises en tant qu'inhibiteurs de proteines kinases
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
EP1871773A1 (fr) * 2005-03-17 2008-01-02 Novartis AG N-[3-(1-amin0-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yle)-phenyl] benzamides utilises en tant qu'inhibiteurs de tyrosine/threonine kinase, en particulier la b-raf kinase
WO2006124780A2 (fr) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
WO2006124731A2 (fr) 2005-05-12 2006-11-23 Irm Llc Composes et compositions utilise(e)s en tant qu'inhibiteurs de proteines-kinases
GT200600197A (es) * 2005-05-13 2007-03-28 Compuestos y composiciones como inhibidores de proteina quinasa
US7846941B2 (en) * 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
CN101263142A (zh) * 2005-05-20 2008-09-10 阿雷生物药品公司 Raf抑制剂化合物及其使用方法
MX2007016463A (es) 2005-06-22 2008-03-04 Plexxikon Inc Derivados de pirrolo [2,3-b] piridina como inhibidores de proteina cinasa.
CN101208338B (zh) 2005-07-29 2010-12-29 霍夫曼-拉罗奇有限公司 氮杂苯并咪唑衍生物，它们的制备以及作为抗癌剂的应用
BRPI0614804A2 (pt) * 2005-08-09 2011-04-12 Irm Llc compostos e composições como inibidores de proteìna cinase
RU2008112313A (ru) * 2005-09-01 2009-10-10 Эррэй Биофарма Инк. (Us) Соединения ингибиторы raf и способы их применения
CN101263145B (zh) * 2005-09-15 2015-02-25 霍夫曼-拉罗奇有限公司 4-氨基-噻吩并[3,2-c]吡啶-7-羧酸衍生物
US20080255184A1 (en) * 2005-11-04 2008-10-16 Smithkline Beecham Corporation Thienopyridine B-Raf Kinase Inhibitors
ZA200804679B (en) * 2005-12-08 2010-02-24 Millenium Pharmaceuticals Inc Bicyclic compounds with kinase inhibitory activity
BRPI0620462A2 (pt) * 2005-12-22 2011-11-16 Astrazeneca Ab composto, processo para preparar um composto, composição farmacêutica, uso de um composto, e,métodos para produzir um efeito inibidor de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença
WO2007076460A2 (fr) 2005-12-23 2007-07-05 Kalypsys, Inc. Nouveaux thiazole-urees substitues utiles en tant qu'inhibiteurs de proteine-kinases
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
US20070155746A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
JP2009532449A (ja) * 2006-04-05 2009-09-10 アストラゼネカ アクチボラグ 抗癌活性のある置換キナゾリン
CN101415688A (zh) * 2006-04-05 2009-04-22 阿斯利康(瑞典)有限公司 具有b-raf抑制活性的喹唑啉酮衍生物
WO2007119055A1 (fr) * 2006-04-18 2007-10-25 Astrazeneca Ab Derives de quinazolin-4-one, procede de fabrication de ces derives et compositions pharmaceutiques les contenant
CA2662031A1 (fr) 2006-09-06 2008-03-13 F. Hoffmann-La Roche Ag Derives heteroaryles utilises en tant qu'inhibiteurs de proteine kinase
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR101101675B1 (ko) * 2006-10-02 2011-12-30 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
WO2008044688A1 (fr) 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Dérivé de l'urée
EP1914234A1 (fr) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
US7872018B2 (en) * 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
WO2008112695A2 (fr) 2007-03-12 2008-09-18 Irm Llc Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci
WO2008124393A1 (fr) 2007-04-04 2008-10-16 Irm Llc Derives de benzothiazole et leur utilisation en tant qu'inhibiteurs des proteines kinases
WO2008144253A1 (fr) 2007-05-14 2008-11-27 Irm Llc Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
JP2010529990A (ja) * 2007-06-15 2010-09-02 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤およびそれを使用するための方法
AU2008265843B2 (en) * 2007-06-21 2012-02-09 Irm Llc Protein kinase inhibitors and methods for using thereof
AU2008276063B2 (en) * 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009025358A1 (fr) * 2007-08-23 2009-02-26 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son utilisation
WO2009028629A1 (fr) * 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son utilisation
WO2009111277A1 (fr) * 2008-02-29 2009-09-11 Array Biopharma Inc. Dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de raf
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
TW200940539A (en) * 2008-02-29 2009-10-01 Array Biopharma Inc RAF inhibitor compounds and methods of use thereof
SG10201608813PA (en) * 2008-03-17 2016-12-29 Ambit Biosciences Corp Quinazoline derivatives as raf kinase modulators and methods of use thereof
GB0807609D0 (en) * 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PE20091846A1 (es) * 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
WO2009143018A2 (fr) * 2008-05-19 2009-11-26 Plexxikon, Inc. Composés et procédés de modulation des kinases, et indications associées
US8119637B2 (en) * 2008-06-10 2012-02-21 Plexxikon Inc. Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
WO2009152087A1 (fr) * 2008-06-10 2009-12-17 Plexxikon, Inc. Composés hétéroaryles bicycliques et procédés destinés à la modulation de kinases, et des indications pour celle-ci
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물

Also Published As

Publication number Publication date
PE20091561A1 (es) 2009-10-30
CL2009000447A1 (es) 2010-01-04
US8338452B2 (en) 2012-12-25
WO2009111278A2 (fr) 2009-09-11
KR20100122505A (ko) 2010-11-22
EP2265608A2 (fr) 2010-12-29
JP2011513330A (ja) 2011-04-28
US20110110889A1 (en) 2011-05-12
AU2009222143A1 (en) 2009-09-11
CA2716951A1 (fr) 2009-09-11
ECSP10010510A (es) 2010-10-30
CN102015707A (zh) 2011-04-13
IL207843A0 (en) 2010-12-30
TW200940540A (en) 2009-10-01
AR070535A1 (es) 2010-04-14
WO2009111278A3 (fr) 2010-07-15
MX2010009410A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
MA32271B1 (fr) Composes inhibiteurs de kinases raf et procedes d'utilisation
MA34234B1 (fr) Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
MA29310B1 (fr) Composes inhibiteurs de raf et procedes
SG178899A1 (en) Raf inhibitor compounds and methods of use thereof
SG178900A1 (en) Raf inhibitor compounds and methods of use thereof
MA33614B1 (fr) Composés de benzoxépine inhibiteurs de pi3k et leurs procédés d'utilisation
PH12013501779B1 (en) Pyrrolopyridines as kinase inhibitors
WO2010003022A8 (fr) Dérivés d'isoindolone utilisés en tant qu'inhibiteurs de kinase mek et procédés d'utilisation correspondants
MY158829A (en) 5-anilinoimidazopyridines and methods of use
MA31339B1 (fr) Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation
PL2231662T3 (pl) 8-anilinoimidazopirydyny oraz ich zastosowanie jako czynników przeciwnowotworowych i/lub przeciwzapalnych
MX2021004410A (es) Inhibidores de la proteina tirosina fosfatasa.
TW200801012A (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
UA116774C2 (uk) Інгібітори серин/треонінкінази
PH12013502369A1 (en) Diazacarbazoles and methods of use
WO2007146824A3 (fr) Quinolines et méthodes d'utilisation
WO2008157179A3 (fr) Azaindoles n-substitués et procédés d'utilisation
MA31146B1 (fr) Composes inhibant la phosphoinositide 3 kinase et procedes d'utilisation
MX2011009167A (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
MX2009012163A (es) Hetarilanilinas como moduladores para beta-amiloide.
MX2010002543A (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
MA30952B1 (fr) Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt
TN2012000192A1 (fr) N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase
NO20081595L (no) Raf-inhibitorforbindelser og fremgangsmater for anvendelse derav